Skip to Content
Merck
CN
  • Mycolactone suppresses T cell responsiveness by altering both early signaling and posttranslational events.

Mycolactone suppresses T cell responsiveness by altering both early signaling and posttranslational events.

Journal of immunology (Baltimore, Md. : 1950) (2010-01-01)
Sheerazed Boulkroun, Laure Guenin-Macé, Maria-Isabel Thoulouze, Marc Monot, Anaïs Merckx, Gordon Langsley, Georges Bismuth, Vincenzo Di Bartolo, Caroline Demangel
ABSTRACT

Mycolactone is a diffusible lipid toxin produced by Mycobacterium ulcerans, the causative agent of a necrotizing skin disease referred to as Buruli ulcer. Intriguingly, patients with progressive lesions display a systemic suppression of Th1 responses that resolves on surgical excision of infected tissues. In this study, we examined the effects of mycolactone on the functional biology of T cells and identified two mechanisms by which mycolactone suppresses cell responsiveness to antigenic stimulation. At noncytotoxic concentrations, mycolactone blocked the activation-induced production of cytokines by a posttranscriptional, mammalian target of rapamycin, and cellular stress-independent mechanism. In addition, mycolactone triggered the lipid-raft association and activation of the Src-family kinase, Lck. Mycolactone-mediated hyperactivation of Lck resulted in the depletion of intracellular calcium stores and downregulation of the TCR, leading to impaired T cell responsiveness to stimulation. These biochemical alterations were not observed when T cells were exposed to other bacterial lipids, or to structurally related immunosuppressors. Mycolactone thus constitutes a novel type of T cell immunosuppressive agent, the potent activity of which may explain the defective cellular responses in Buruli ulcer patients.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-PLCγ-1 Antibody, clone B-6-4, clone B-6-4, 1 mg/mL, Upstate®